| Nov 4 |
Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme
|
| Oct 16 |
Kazia Therapeutics Adjusts ADS Ratio to Boost Nasdaq Listing
|
| Oct 2 |
Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American Societ...
|
| Sep 12 |
Kazia Therapeutics enters into licensing agreement with QIMR Berghofer
|
| Sep 12 |
KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFER
|
| Jul 25 |
Biotech Stock Laboratory: Try a Small Experiment With Kazia Therapeutics
|
| Jul 12 |
Kazia Therapeutics (KZIA) Soars 490% in a Week: Here's Why
|
| Jul 12 |
From Pennies to Dollars: 3 Sub-$5 Stocks Set to Explode Higher
|
| Jul 11 |
Kazia Therapeutics stocks soar following Phase II/III win
|
| Jul 10 |
Why SeaStar Medical Holding Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
|
